18004-75-6 Usage
Uses
Used in Pharmaceutical Drug Synthesis:
2-Methyl-5,6,7,8-tetrahydroquinolin-4-ol is utilized as a key intermediate in the synthesis of pharmaceutical drugs. Its distinctive molecular structure contributes to the development of new medications, enhancing the therapeutic potential of various treatments.
Used in Organic Compound Synthesis:
Beyond its pharmaceutical applications, 2-Methyl-5,6,7,8-tetrahydroquinolin-4-ol is also employed in the synthesis of other organic compounds. Its reactivity and structural features are instrumental in creating a range of chemical products, broadening its utility across different industries.
Used in Medicinal Chemistry Research:
In the realm of medicinal chemistry, 2-Methyl-5,6,7,8-tetrahydroquinolin-4-ol serves as a subject of research to explore its potential uses. Scientists study its properties and reactivity to understand how it can be leveraged in the creation of novel therapeutic agents.
Used in Drug Development:
2-METHYL-5,6,7,8-TETRAHYDROQUINOLIN-4-OL plays a significant role in drug development, where its unique characteristics are harnessed to design and improve pharmaceutical formulations. This contributes to the advancement of medicine by potentially leading to more effective and safer drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 18004-75-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,8,0,0 and 4 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 18004-75:
(7*1)+(6*8)+(5*0)+(4*0)+(3*4)+(2*7)+(1*5)=86
86 % 10 = 6
So 18004-75-6 is a valid CAS Registry Number.
InChI:InChI=1S/C10H13NO/c1-7-6-10(12)8-4-2-3-5-9(8)11-7/h6H,2-5H2,1H3,(H,11,12)
18004-75-6Relevant academic research and scientific papers
Nucleoside analogs useful as PRMT5 inhibitors
-
Paragraph 0181; 0183; 0187; 0188; 0189, (2021/08/11)
The invention relates to the technical field of biological medicines, and particularly discloses a nucleoside analogue used as a PRMT5 inhibitor. According to the nucleoside analogue as shown in the formula (I) or the pharmaceutically acceptable salt of the nucleoside analogue, the nucleoside analogue or the pharmaceutically acceptable salt of the nucleoside analogue shows relatively high inhibition on the activity of PRMT5 and can be used for preventing and/or treating PRMT5-mediated diseases, and the PRMT5-mediated diseases comprise cell abnormal proliferative diseases.
CYCLIC BISOXIME MICROBICIDES
-
Page/Page column 84; 85, (2013/07/05)
The invention relates to compounds of formula (I) wherein A, X, Y1, Y3, Y4, Y6, D1, D2, D3, G1, G2, G3 and p are as defined in the claims. The in
NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES
-
Page/Page column 113-114, (2012/02/13)
The present invention provides compounds of formula (I) wherein G1, G2, G3, G4, G5, G6, Y1, Y2, Y3, Y4, Y5 and Y6 and p and
NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES
-
Page/Page column 108, (2012/01/14)
The present invention provides compounds of formula (I) wherein R1, A1, X, Y6, Y7, Y8, G1, G2, G3 and p are as defined in the claims. The invention further provides in
NOVEL MICROBIOCIDAL OXIME ETHERS
-
Page/Page column 114, (2012/09/21)
The present invention provides compounds of formula (I) wherein D1, D2, D3, G1, G2, G3, Y3, Y4, Y6, p and X are as defined in the claims. The invention furt
